CHRS: Coherus Biosciences Inc Company Profile & Statistics

About

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.

Info & Links

CEO

Dennis M. Lanfear

Headquarters

333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY, CA 94065, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

306

Coherus Biosciences Inc Statistics

Valuation Measures

Market Capitalization²

179.73M

Enterprise Value

346.55M

Enterprise Value/EBITDA(ttm)

-2.61

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

0.61

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

47.44%

Operating Margin(ttm)

-51.65%

Profit Margin(ttm)

2.85%

Return on Equity(ttm)

Return on Invested Capital(ttm)

5.51%

Return on Assets(ttm)

-24.44%

Income Statement

Revenue(ttm)

304.34M

Revenue Per Share(ttm)

2.64

Gross Profit(ttm)

136.08M

EBITDA(ttm)³

-133.02M

Net Income Available to Common(ttm)

-450.00K

Diluted EPS(ttm)

-0.08

Share Statistics

Beta (5Y Monthly)

0.86

52-Week Change

-32.17%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

115.21M

Dividend Yield

0.00%

Float⁴

106.42M

% Held by Insiders

7.63%

% Held by Institutions

72.82%

Balance Sheet

Total Cash(mrq)

97.69M

Total Cash Per Share(mrq)

0.85

Total Debt(mrq)

264.51M

Total Debt/Equity(mrq)

-300.67%

Current Ratio(mrq)

1.25%

Quick Ratio(mrq)

1.09%

Book Value Per Share(mrq)

-0.76

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.43

Free Cash Flow(ytd)

-49.05M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CHRS

Coherus Biosciences Inc

Coherus Biosciences Inc Profile